Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram.

J Morganroth, L N Horowitz

The American Journal of Cardiology

|February 27, 1984

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A thorough electrocardiogram study of edoxaban, a novel factor Xa inhibitor.

Journal of clinical pharmacology·2011

Same author

Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study.

Clinical pharmacology and therapeutics·2010

Same author

Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval).

Clinical pharmacology and therapeutics·2009

Same author

Cardiac repolarization and the safety of new drugs defined by electrocardiography.

Clinical pharmacology and therapeutics·2006

Same author

Evaluation of the effect on cardiac repolarization (QTc interval) of oncologic drugs.

Ernst Schering Research Foundation workshop·2006

Same author

Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval.

British journal of clinical pharmacology·2001

Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026

Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026

Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026

Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026

Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026

Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026

See all related articles

Flecainide acetate, a class IC anti-arrhythmic, shows low proarrhythmic potential in chronic ventricular arrhythmias. However, it may increase risks in acute, severe arrhythmias, especially with left ventricular dysfunction.

Area of Science:

Pharmacology
Clinical Electrophysiology
Cardiology

Background:

Flecainide acetate is a potent class IC anti-arrhythmic agent.
Understanding its proarrhythmic potential and electrophysiologic effects is crucial for patient management.

Purpose of the Study:

To evaluate the proarrhythmic potential of flecainide acetate.
To assess the electrophysiologic effects of flecainide acetate.

Main Methods:

Review of data on flecainide acetate in patients with chronic and acute ventricular arrhythmias.
Comparison with other anti-arrhythmic agents like quinidine and encainide.
Analysis of electrocardiographic changes, including PR, QRS, and QT intervals.

Main Results:

Related Experiment Videos

Proarrhythmic effects observed in 0-4% of chronic ventricular arrhythmia patients, compared to 1-8% for quinidine and 2% for encainide.
Proarrhythmic effects noted in 5-12% of acute, hemodynamically significant ventricular arrhythmia patients.
Increased PR and QRS intervals (approx. 25%) at therapeutic levels, without significant clinical implications; minimal QT prolongation.

Conclusions:

Flecainide acetate demonstrates a low proarrhythmic potential in chronic ventricular arrhythmias.
Proarrhythmic effects are more prevalent in patients with left ventricular dysfunction and life-threatening arrhythmias.
Electrophysiologic effects, including PR and QRS prolongation, are generally not clinically significant and do not warrant discontinuation; QT prolongation is minimal.